Mega Doctor News
- Advertisement -
By George Washington University
Newswise – With Alzheimer’s rates climbing and diagnoses often delayed until symptoms progress, a new FDA-cleared blood test could mark a turning point in how the disease is identified and managed.
This week, the FDA cleared Roche’s Elecsys pTau181 test — only the second blood-based biomarker test approved this year for Alzheimer’s disease. The test, developed with Eli Lilly, gives primary care physicians a faster way to help rule out Alzheimer’s in patients showing signs of cognitive decline, potentially reducing reliance on costly PET scans and getting patients to answers — and treatment — sooner.
- Advertisement -
